<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151741">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01124669</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000670998</org_study_id>
    <secondary_id>ECOG-E2501T2</secondary_id>
    <nct_id>NCT01124669</nct_id>
  </id_info>
  <brief_title>Biomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib Tosylate</brief_title>
  <official_title>BRAF, KRAS and EGFR Mutation Detection in Non-Small Cell Lung Cancer Patients Treated With Sorafenib Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help
      doctors learn more about changes that occur in DNA and identify biomarkers related to
      cancer.

      PURPOSE: This research study is studying biomarkers in blood samples from patients with
      refractory non-small cell lung cancer previously treated with sorafenib tosylate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To determine the mutation rates of BRAF, KRAS, and EGFR in patients with non-small cell
           lung cancer treated with sorafenib tosylate on protocol ECOG-2501.

        -  To determine the association between BRAF, KRAS, or EGFR mutation status and clinical
           benefits in patients treated with this regimen.

      OUTLINE: This is a multicenter study.

      DNA is isolated from archived plasma samples and analyzed for BRAF, KRAS, and EGFR
      mutations.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <primary_completion_date type="Anticipated">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Mutation rate of sorafenib tosylate-target gene BRAF, and its upstream proteins KRAS and EGFR</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Association between BRAF, KRAS, and EGFR mutation status and clinical benefits (stable disease or partial response)</measure>
  </primary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of refractory non-small cell lung cancer

          -  Received sorafenib tosylate on protocol ECOG-E2501

          -  Available blood specimens

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Chung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <verification_date>May 2010</verification_date>
  <lastchanged_date>July 7, 2010</lastchanged_date>
  <firstreceived_date>May 14, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Robert L. Comis</name_title>
    <organization>ECOG Group Chair's Office</organization>
  </responsible_party>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
